Chemokine Therapeutics announces addition to senior management team

    TSX: CTI

    VANCOUVER, March 22 /CNW/ - Chemokine Therapeutics Corp. ("Chemokine
Therapeutics" or the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company
developing chemokine-based therapies to treat cancer, blood disorders, and
vascular disease today announced the appointment of C. Richard Piazza as its
new Chief Executive Officer (CEO). Mr. Piazza succeeds Dr. Hassan Salari who
held the position since he founded the Company in 1998. Dr. Salari will
continue to serve the Company as President and his role will be expanded to
include the additional responsibilities as the Chief Scientific Officer. These
changes will allow Dr. Salari to focus on Chemokine's accelerating product
development while Mr. Piazza will use his financial and biotechnology industry
experience to drive corporate initiatives.
    "I look forward to leading the team at Chemokine through its next stages
of growth," said Richard Piazza. "We will focus on creating value and
stimulating the growth of the Company as it continues through its clinical
trials. With positive preliminary results announced recently regarding our
lead candidate, CTCE-9908, this is a very exciting time for me to assume the
CEO role position at Chemokine Therapeutics."
    Mr. Piazza has been a member of the board of directors for Chemokine
Therapeutics since June 2001 and is presently the Chairman of the Board. Mr.
Piazza has over 35 years of experience managing both public and VC-backed
healthcare companies ranging from startup device and biotechnology companies
to firms with combined annual revenues of over $600 million. He is currently
Managing Director of Healthios, a healthcare merchant banking firm. He has
served in numerous CEO positions including MAXIA Pharmaceuticals, VitaGen
Inc., Marquest, Smith & Nephew SoloPak, Stimetics and Biolectron. With
experience that includes all sectors or healthcare (pharmaceuticals,
biotechnology, devices & services), Mr. Piazza has created a reputation as a
focused operating manager with intimate knowledge of the healthcare industry's
dynamics. He has an established track record in high growth companies, new
technology development and product launches. In addition to his operating
experience, Mr. Piazza has helped to raise over $150 million in both the
private equity and public markets and has worked extensively with many of the
premier healthcare venture capital funds.

    About CTCE-9908
    CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist
of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine
that binds to CXCR4, which is present on many cancer cells. This binding
process is believed to be critical in angiogenesis and in the metastasis (or
spread) of cancer cells to distant locations in the body, where they form new
tumors. Approximately 90% of cancer deaths are due to metastasis. We believe
that CTCE-9908 interferes with the metastatic process of cancers by both
preventing them to spread and blocking the blood supply to the cancer cells.

    About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
    Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class of
signaling proteins that play a critical role in the growth, differentiation,
and maturation of cells necessary for fighting infection as well as tissue
repair and regeneration. Chemokines also have an important role in cancer
metastasis and growth. Chemokine Therapeutics is a leader in research in the
field of chemokines and has several product candidates in various stages of

    Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: Statements in this document regarding managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual
results to differ materially from the statements made. For this purpose, any
statements that are contained herein that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "projects", and similar expressions are intended to
identify forward-looking statements. You are cautioned that such statements
are subject to a multitude of risks and uncertainties that could cause actual
results, future circumstances, or events to differ materially from those
projected in the forward-looking statements. These risks include, but are not
limited to, those associated with the success of research and development
programs, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company's
public disclosure documents and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the Company
disclaims any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.

For further information:

For further information: Chemokine Therapeutics Corp., Mr. Don Evans,
Director of Public Relations, Phone: (604) 822-0305, or 1-888-822-0305, Fax:
(604) 822-0302, E-mail:, Internet:;
Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext.
233, Fax: (416) 815-0080, E-mail:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890